ABT-143 + simvastatin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Conditions
Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Trial Timeline
Nov 1, 2008 → Jun 1, 2009
NCT ID
NCT00812955About ABT-143 + simvastatin
ABT-143 + simvastatin is a phase 3 stage product being developed by AstraZeneca for Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00812955. Target conditions include Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia.
What happened to similar drugs?
15 of 20 similar drugs in Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia were approved
Approved (15) Terminated (3) Active (3)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00812955 | Phase 3 | Completed |
Competing Products
20 competing products in Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia